Acute correction of anemia with EPO and new agents that increase endogenous EPO production, the hypoxia‐inducible factor‐prolylhydroxylase inhibitors (HIF‐PHI), have been shown to fully rescue complete blood counts in the adenine‐CKD model (Noonan et al., 2020, 2021). This evidence concerns the gene EPO and chronic kidney disease.